Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure−Activity Studies

The structure-based design, chemical synthesis, and biological evaluation of various peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 1998-07, Vol.41 (15), p.2819-2834
Hauptverfasser: Dragovich, Peter S, Webber, Stephen E, Babine, Robert E, Fuhrman, Shella A, Patick, Amy K, Matthews, David A, Reich, Siegfried H, Marakovits, Joseph T, Prins, Thomas J, Zhou, Ru, Tikhe, Jayashree, Littlefield, Ethel S, Bleckman, Ted M, Wallace, Michael B, Little, Thomas L, Ford, Clifford E, Meador, James W, Ferre, Rose Ann, Brown, Edward L, Binford, Susan L, DeLisle, Dorothy M, Worland, Stephen T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The structure-based design, chemical synthesis, and biological evaluation of various peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic modification of each amino acid residue present in the binding determinant as well as the N-terminal functionality is described. Such modifications are shown to provide irreversible HRV-14 3CP inhibitors with anti-3CP activities (k obs/[I]) ranging from 60 to 280 000 M-1 s-1 and antiviral EC50's which approach 0.15 μM. An optimized inhibitor which incorporates several improvements identified by the structure−activity studies is also described. This molecule displays very rapid irreversible inhibition of HRV-14 3CP (k obs/[I] = 800 000 M-1 s-1) and potent antiviral activity against HRV-14 in cell culture (EC50 = 0.056 μM). A 1.9 Å crystal structure of an S-alkylthiocarbamate-containing inhibitor complexed with HRV-2 3CP is also detailed.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm9800696